[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) has submitted a Form 144 reporting a proposed sale of 150,000 common shares through UBS Financial Services with an aggregate market value of $3,294,454.97. The shares were acquired on 09/18/2025 via an equity option exercise from Surgery Partners, Inc., and the planned sale is listed for 09/18/2025 on NASDAQ. The filing also discloses multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including transactions of 100,000 shares on 08/21/2025 and 09/11/2025 and several smaller sales, each with stated gross proceeds. The notice includes the signers representation that they are not aware of undisclosed material adverse information about the issuer.

Positive

• None.

Negative

• Planned sale of 150,000 shares with an aggregate market value of $3,294,454.97 filed for sale on 09/18/2025 through UBS.
• Multiple recent insider sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including two transactions of 100,000 shares, indicating substantial insider disposition activity.

Insights

Financial Analyst

TL;DR: Significant insider selling reported; timing aligns with option exercise and immediate sale through UBS.

The filing shows an insider exercising equity compensation and proposing an immediate sale of 150,000 common shares valued at about $3.29 million. Prior transactions by Wayne DeVeydt between late August and mid-September 2025 document repeated disposals of company stock, including two large 100,000-share transactions. From a trading-flow perspective, this pattern reflects exercise-and-sell activity rather than a single isolated sale; investors should note the volume but the filing does not state any nonpublic adverse information or change in company operations.

Corporate Governance Expert

TL;DR: Recurrent insider sales and same-day exercise-and-sell warrant governance attention.

The report evidences equity option exercise on 09/18/2025 followed by a proposed sale the same day, and a series of recent dispositions by an individual (Wayne DeVeydt). While such behavior is common with option liquidity, repeated large sales can raise questions about insider alignment with shareholders. The filing, however, contains the standard attestation that no material undisclosed information is known to the seller; no further governance disclosures are provided within this form.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	150000	3294454.97	128209410	09/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/18/2025	equity compensation	Surgery Partners, Inc.			150000	09/18/2025	equity option exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	572717
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/27/2025	11865	271756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/02/2025	25000	562150
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/03/2025	25000	560251
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/04/2025	25000	562756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/05/2025	25000	563682
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/08/2025	2014	45207
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/11/2025	100000	2200741
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/12/2025	28700	628929
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/16/2025	25000	541518
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/17/2025	85785	1873875

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Surgery Partners (SGRY) report?

The Form 144 reports a proposed sale of 150,000 common shares valued at $3,294,454.97, acquired via equity compensation and listed for sale on 09/18/2025 through UBS on NASDAQ.

Who acquired the shares being offered and how were they acquired?

The shares were acquired on 09/18/2025 by the reporting person through an equity option exercise from Surgery Partners, Inc.

Has the filer recently sold other Surgery Partners shares?

Yes. The filing lists multiple sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including sales of 100,000 shares on 08/21/2025 and 09/11/2025 with listed gross proceeds.

Through which broker is the proposed sale being executed?

The proposed sale is to be executed through UBS Financial Services Inc, located at 1000 Harbor Blvd, Weehawken, NJ, and listed for sale on NASDAQ.

Does the Form 144 indicate any undisclosed material information about Surgery Partners?

The signer represents by the notice signature that they do not know any material adverse information about the issuer that has not been publicly disclosed; the filing contains no additional disclosures of nonpublic information.